DE60226881D1 - High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen - Google Patents

High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen

Info

Publication number
DE60226881D1
DE60226881D1 DE60226881T DE60226881T DE60226881D1 DE 60226881 D1 DE60226881 D1 DE 60226881D1 DE 60226881 T DE60226881 T DE 60226881T DE 60226881 T DE60226881 T DE 60226881T DE 60226881 D1 DE60226881 D1 DE 60226881D1
Authority
DE
Germany
Prior art keywords
treatment
impact
density lipoprotein
ischemia state
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226881T
Other languages
German (de)
English (en)
Inventor
Alphonse Hubsch
Markus G Lang
Peter G Lerch
Roberto Paterno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
ZLB Bioplasma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by ZLB Bioplasma AG filed Critical ZLB Bioplasma AG
Application granted granted Critical
Publication of DE60226881D1 publication Critical patent/DE60226881D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
DE60226881T 2001-08-20 2002-08-20 High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen Expired - Lifetime DE60226881D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (1)

Publication Number Publication Date
DE60226881D1 true DE60226881D1 (de) 2008-07-10

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226881T Expired - Lifetime DE60226881D1 (de) 2001-08-20 2002-08-20 High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen

Country Status (10)

Country Link
US (2) US20040266660A1 (cg-RX-API-DMAC7.html)
EP (1) EP1425031B8 (cg-RX-API-DMAC7.html)
JP (1) JP4284177B2 (cg-RX-API-DMAC7.html)
AT (1) ATE396736T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002340825B2 (cg-RX-API-DMAC7.html)
CA (1) CA2457840C (cg-RX-API-DMAC7.html)
DE (1) DE60226881D1 (cg-RX-API-DMAC7.html)
ES (1) ES2304452T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003018047A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401360B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
WO2010151096A1 (en) 2009-06-25 2010-12-29 Tetra, Sia Therapeutic combinations of nicotinic acid and meldonium
WO2011006994A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US20120189612A1 (en) * 2011-01-25 2012-07-26 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
CN105288589A (zh) 2011-02-07 2016-02-03 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
EP2688584A4 (en) * 2011-03-25 2015-05-20 Univ Columbia PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
US20230372532A1 (en) * 2020-10-05 2023-11-23 Northwestern University Targeted ph sensitive liposomes
US20240215570A1 (en) 2021-04-15 2024-07-04 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
US7491693B2 (en) 2009-02-17
CA2457840C (en) 2011-10-11
EP1425031A2 (en) 2004-06-09
ES2304452T3 (es) 2008-10-16
HK1064304A1 (en) 2005-01-28
WO2003018047A2 (en) 2003-03-06
US20080108550A1 (en) 2008-05-08
JP4284177B2 (ja) 2009-06-24
AU2002340825B2 (en) 2007-07-05
ATE396736T1 (de) 2008-06-15
US20040266660A1 (en) 2004-12-30
CA2457840A1 (en) 2003-03-06
ZA200401360B (en) 2005-08-31
EP1425031B1 (en) 2008-05-28
JP2005501110A (ja) 2005-01-13
WO2003018047A3 (en) 2004-01-29
EP1425031B8 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
DE60226881D1 (de) High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE477816T1 (de) Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
EA201001081A1 (ru) Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
WO2006130553A3 (en) Hcv protease inhibitors
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE327250T1 (de) Kristallstruktur von ribosomen und proteinsynthese-inhibitoren
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
SE0004101D0 (sv) New use
EA200201232A1 (ru) Производные сульфонамида
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
DK0676961T3 (da) Anvendelse af macrolider til behandling af cerebral iskæmi
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
DE60100431D1 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
TW200505872A (en) Hepatitis C virus inhibitors
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CSL BEHRING AG, BERN, CH

8364 No opposition during term of opposition